- My Portfolio
- News
- Markets
- Stocks: Most Actives
- Stocks: Gainers
- Stocks: Losers
- Trending Tickers
- Futures
- World Indices
- US Treasury Bonds Rates
- Currencies
- Crypto
- Top ETFs
- Top Mutual Funds
- Options: Highest Open Interest
- Options: Highest Implied Volatility
- Sectors
- Basic Materials
- Communication Services
- Consumer Cyclical
- Consumer Defensive
- Energy
- Financial Services
- Healthcare
- Industrials
- Real Estate
- Technology
- Utilities
- Research
- Personal Finance
- Videos
New on Yahoo
New on Yahoo
© 2024 All rights reserved.
Yahoo Finance
Yahoo Finance- My Portfolio
- News
- Markets
- Stocks: Most Actives
- Stocks: Gainers
- Stocks: Losers
- Trending Tickers
- Futures
- World Indices
- US Treasury Bonds Rates
- Currencies
- Crypto
- Top ETFs
- Top Mutual Funds
- Options: Highest Open Interest
- Options: Highest Implied Volatility
- Sectors
- Basic Materials
- Communication Services
- Consumer Cyclical
- Consumer Defensive
- Energy
- Financial Services
- Healthcare
- Industrials
- Real Estate
- Technology
- Utilities
- Research
- Personal Finance
- Videos
AllQuantitative Report
Argus•October 02, 2024
Argus•October 02, 2024CPRX: Lowering target price to $21.00
Summary
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitat
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- DVAX: What does Argus have to say about DVAX?Oct 02, 2024 •
DVAX
- BMRN: Raising target price to $74.00Oct 02, 2024 •
BMRN
- NBIX: Lowering target price to $120.00Oct 02, 2024 •
NBIX
- CYTK: Rating increased to a HOLDOct 02, 2024 •
CYTK
- CORT: Raising target price to $49.00Oct 02, 2024 •
CORT